TransCon PTH as a Hormone Replacement Therapy for Patients with Hypoparathyroidism: 6-Month Update from the PaTH Forward Open-Label Extension

Background: Hypoparathyroidism (HP) is characterized by insufficient levels of parathyroid hormone (PTH), resulting in hypocalcemia, hyperphosphatemia, hypercalciuria, and a reduced quality of life (QoL). PTH replacement therapy should restore physiologic levels of PTH and restore downstream physiol...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubin, Mishaela R, Rejnmark, Lars, Schwarz, Peter E, Vokes, Tamara J, Clarke, Bart, Ahmed, Intekhab, Hofbauer, Lorenz C, Palermo, Andrea, Marcocci, Claudio, Pagotto, Uberto, Eriksen, Erik F, Mourya, Sanchita, Markova, Denka, Pihl, Susanne, Shu, Aimee D, Khan, Aliya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Bone and Mineral Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090331/
http://dx.doi.org/10.1210/jendso/bvab048.514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090331/
http://dx.doi.org/10.1210/jendso/bvab048.514

Ejemplares similares